Professor Howard Federoff joins Board of Vivifi Biotech

24 September 2021

Parkinson’s Virtual Biotech is pleased to announce the appointment of world-leading Parkinson’s expert, Professor Howard Federoff MD PhD, as a Director of Vivifi Biotech.

Vivifi Biotech launched in February 2021 to drive forward planning for the further development of device-delivered GDNF, a treatment approach that holds great potential for slowing, stopping or even reversing Parkinson’s.

Howard was recently a professor of neurology at the University of California and has dedicated his career to advancing pioneering therapeutics for Parkinson’s and other neurological conditions. He has founded and led several biotech companies with interests in Parkinson's, including in neurotrophic factors, gene therapies and stem cell therapies.

Howard is currently President and CEO of Brooklyn Immunotherapeutics, a platform company developing mRNA-based cellular engineering and gene editing and cytokines drug products.

His appointment brings independent scientific and business experience to support Vivifi Biotech’s mission to create a definitive new trial of GDNF for Parkinson’s.

Howard comments on his new role:

“The thoughtful and rigorous prosecution of GDNF for Parkinson’s is essential to establish its potential benefit for patients. I’m delighted to join the board and contribute to the team’s effort to bring this therapeutic candidate forward.”

Peter Miller, Parkinson’s UK Trustee and Chair of the Board of Directors for Vivifi Biotech, adds:

“I am delighted to welcome Howard onto the Vivifi Biotech Board. His expertise in the field of advanced therapeutics for Parkinson’s is exceptional and will be critical as we take forward our plans to create a definitive new trial of this complex therapy. We look forward to working with him to explore this potentially transformative approach for the millions of people affected by Parkinson’s.”